Blueprint Medicines Corporation (BPMC)

Blueprint Medicines Revenue

Blueprint Medicines had revenue of $149.41M in the quarter ending March 31, 2025, with 55.45% growth. This brings the company's revenue in the last twelve months to $562.12M, up 99.19% year-over-year. In the year 2024, Blueprint Medicines had annual revenue of $508.82M with 104.04% growth.

• Revenue (ttm): $562.12M
• Revenue Growth: +99.19%
• P/S Ratio: 14.48
• Revenue / Employee: $866,134
• Employees: 649
• Market Cap: 8.29B

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2024	508.82M	259.44M	104.04%
Dec 31, 2023	249.38M	45.34M	22.22%
Dec 31, 2022	204.04M	23.96M	13.30%
Dec 31, 2021	180.08M	-613.66M	-77.31%
Dec 31, 2020	793.74M	727.22M	1,093.37%

Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.